NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
South San Francisco, Calif., Dec. 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
South San Francisco, Calif., Dec. 8, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
South San Francisco, Calif., Dec. 7, 2020 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
- Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels–including 1 CR, 3 cPRs and 6 uPRs - - Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment - - Dose-expansion has been intiated to...
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro’s Board - SOUTH SAN FRANCISCO, Calif., Dec. 1, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and...
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
– Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PTon Dec. 3rd – SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences...
